← Leaderboards
Cassian Yee
University Of Tx Md Anderson Can Ctr
$17,221,393
Attributed
$20,989,902
Total exposure
24
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,989,902 · 24
By mechanism
R01$6,999,592 · 4
R21$3,880,442 · 6
P50$3,767,612 · 4
UG3$2,717,589 · 1
UH3$2,270,520 · 1
R33$1,166,270 · 1
Top collaborators
- Maria Pia Morelli3 shared
- Kunal Rai3 shared
- Alexandra P Ikeguchi1 shared
- Sapna Patel1 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Maria Pia Morelli$1,662,703
- Alexandra P Ikeguchi$109,006
- Marina Y Konopleva$11,210,192
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaTumorT-LymphocyteAntigensResponseTumor AntigensIn VivoImmunotherapyClinical TrialsSpecificityMalignant NeoplasmsSafetyClinical ResearchDoseCellsImmunogenicNeoplastic CellInfusion ProceduresSourceConventional TherapyImmuneImmune ResponseAdoptive TransferIn Vitro
Grant awards (66)
HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer$2,270,520
UH3 · FY2025 · CA · contact PI
Project 2: Adoptive Cell Therapies for Chordomas$319,676
P50 · FY2025 · CA · contact PI
HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer$1,310,673
UG3 · FY2024 · CA · contact PI
Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell Therapy$218,011
R01 · FY2024 · CA · contact PI
HORMAD-specific TGF-beta resistant memory T cells for treatment of patients with Gastro-esophageal Cancer$1,406,916
UG3 · FY2023 · CA · contact PI
Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma$481,659
P50 · FY2023 · CA · contact PI
Adoptive T Cell Therapy for Pancreatic Cancer$1
R01 · FY2023 · CA · contact PI
Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell Therapy$668,196
R01 · FY2022 · CA · contact PI
Adoptive T Cell Therapy for Pancreatic Cancer$613,867
R01 · FY2022 · CA · contact PI
Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma$416,783
P50 · FY2022 · CA · contact PI
Adoptive T Cell Therapy for Pancreatic Cancer$623,803
R01 · FY2021 · CA · contact PI
Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma$388,908
P50 · FY2021 · CA · contact PI
Adoptive T Cell Therapy for Pancreatic Cancer$623,803
R01 · FY2020 · CA · contact PI
Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma$498,957
P50 · FY2020 · CA · contact PI
T Cell Immunity Of COVID19: Developing Biomarker And Therapeutic Strategies$149,511
R01 · FY2020 · CA · contact PI
Adoptive T Cell Therapy for Pancreatic Cancer$623,803
R01 · FY2019 · CA · contact PI
Project 3 Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma$416,787
P50 · FY2019 · CA · contact PI
Adoptive T cell Therapy of Melanoma Targeting NY-ESO-1$301,062
R01 · FY2014 · CA · contact PI
Adoptive T cell Therapy of Melanoma Targeting NY-ESO-1$291,580
R01 · FY2013 · CA · contact PI
Adoptive T cell Therapy of Melanoma Targeting NY-ESO-1$373,963
R01 · FY2012 · CA · contact PI
Adoptive T cell Therapy of Melanoma Targeting NY-ESO-1$381,343
R01 · FY2011 · CA · contact PI
Adoptive T cell Therapy of Melanoma Targeting NY-ESO-1$392,915
R01 · FY2010 · CA · contact PI
Identification of T Cell-Defined Antigens in Ovarian Cancer$391,253
R33 · FY2010 · CA · contact PI
Adoptive T Cell Therapy Following CD25 Lymphodepletion$350,828
R21 · FY2010 · CA · contact PI
Identification of T Cell-Defined Antigens in Ovarian Cancer$383,582
R33 · FY2009 · CA · contact PI
Adoptive T Cell Therapy Following CD25 Lymphodepletion$351,887
R21 · FY2009 · CA · contact PI
Potentiating Adoptive T Cell Therapy by Immunomodulation$292,160
R21 · FY2009 · CA · contact PI
Identification of T Cell-Defined Antigens in Ovarian Cancer$391,435
R33 · FY2008 · CA · contact PI
Adoptive T Cell Therapy of Melanoma Targeting NY-ESO-1$337,154
R01 · FY2008 · CA · contact PI
Potentiating Adoptive T Cell Therapy by Immunomodulation$323,564
R21 · FY2008 · CA · contact PI
Adoptive T Cell Therapy of Ovarian Cancer$286,393
P50 · FY2008 · CA · contact PI
Identification of T Cell-Defined Antigens in Ovarian Cancer$351,120
R21 · FY2007 · CA · contact PI
Adoptive T Cell Therapy of Melanoma Targeting NY-ESO-1$334,292
R01 · FY2007 · CA · contact PI
Adoptive T Cell Therapy of Ovarian Cancer$328,432
P50 · FY2007 · CA · contact PI
Potentiating Adoptive T Cell Therapy by Immunomodulation$320,440
R21 · FY2007 · CA · contact PI
PHASE I STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY, CD4+$2,433
M01 · FY2007 · RR · contact PI
CONSENT TO PARTICIPATE AS A DONOR OF PERIPHERAL BLOOD MONONUCLEAR CELLS$685
M01 · FY2007 · RR · contact PI
Adoptive T Cell Therapy of Melanoma Targeting NY-ESO-1$334,740
R01 · FY2006 · CA · contact PI
Adoptive T Cell Therapy of Ovarian Cancer$253,218
P50 · FY2006 · CA · contact PI
EVALUATION OF SAFETY USING T CELL CLONES FOR PTS WITH METASTATIC MELANOMA$35,560
M01 · FY2006 · RR · contact PI
PHASE I STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY, CD4+$7,443
M01 · FY2006 · RR · contact PI
CONSENT TO PARTICIPATE AS A DONOR OF PERIPHERAL BLOOD MONONUCLEAR CELLS$4,962
M01 · FY2006 · RR · contact PI
Adoptive T Cell Therapy of Melanoma Targeting NY-ESO-1$333,310
R01 · FY2005 · CA
Adoptive T Cell Therapy of Ovarian Cancer$209,546
P50 · FY2005 · CA
EVALUATION OF SAFETY USING T CELL CLONES FOR PTS WITH MATASTIC MELANOMA$34,231
M01 · FY2005 · RR
PHASE I STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY, CD4+$26,386
M01 · FY2005 · RR
PHASE I STUDY TARGETING CELLULAR ADOPTIVE IMMUNOTHERAPY USING CD8+ IN CANCER-TES$9,985
M01 · FY2005 · RR
CONSENT TO PARTICIPATE AS A DONOR OF PERIPHERAL BLOOD MONONUCLEAR CELLS$4,991
M01 · FY2005 · RR
STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY$1,427
M01 · FY2005 · RR
Adoptive T Cell Therapy Following Lymphodepletion$331,443
R21 · FY2004 · CA
Adoptive T Cell Therapy of Melanoma Targeting NY-ESO-1$331,239
R01 · FY2004 · CA
Adoptive T Cell Therapy of Ovarian Cancer$167,253
P50 · FY2004 · CA
Study to evaluate the safety of cellular adoptive immunotherapy$23,854
M01 · FY2004 · RR
Evaluation of safety using T cell clones for pts with metastatic melanoma$19,084
M01 · FY2004 · RR
Phase I study to evaluate the safety of cellular adoptive immunotherapy$4,771
M01 · FY2004 · RR
Phase I study targeting cellular adoptive immunotherapy in cancer-testis$4,337
M01 · FY2004 · RR
Adoptive T Cell Therapy Following Lymphodepletion$326,812
R21 · FY2003 · CA
Adoptive CD4 T Cell Therapy of Melanoma$338,772
R21 · FY2002 · CA
Therapy of Melanoma with Antigen Specific T Cell Clones$263,623
R21 · FY2002 · CA
EVALUATE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY$0
M01 · FY2002 · RR
Adoptive CD4 T Cell Therapy of Melanoma$333,632
R21 · FY2001 · CA
Therapy of Melanoma with Antigen Specific T Cell Clones$296,161
R21 · FY2001 · CA
EVALUATE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY$0
M01 · FY2001 · RR
THERAPY OF MELANOMA WITH ANTIGEN-SPECIFIC T CELL CLONES$66,999
R01 · FY2000 · CA
EVALUATE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY$3,864
M01 · FY2000 · RR
EVALUATE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY$3,864
M01 · FY2000 · RR